Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a blended e-health intervention designed to improve fear of progression FOP in women with advanced or certain types of gynecologic or breast cancer. Fear of progression refers to the worry patients experience about their cancer growing or worsening, which is linked to distress, depression, and higher health care costs. This trial aims to determine whether the intervention is feasible, acceptable, and effective in reducing FOP and related psychological symptoms. Participants are randomly assigned to one of two groups over six weeks. One group takes part in the Mindful Living Program, which includes weekly group sessions and online sessions focusing on mindfulness and coping skills, daily practice of mindfulness techniques, check-in phone calls, and access to supportive online resources. The other group participates in the Navigating Cancer Program with similar group and online sessions and a check-in call but without the additional mindfulness practices or web resources. After the intervention, participants are followed up at 12 weeks. During the study, participants complete surveys measuring fear of progression, distress, anxiety, metacognitions, and mindfulness at the start, at six weeks, and again at 12 weeks. Researchers also monitor attendance, engagement, usability of the intervention, and recruitment and retention rates. The study includes remote group sessions, check-in calls, and access to online videos, a journal, and a community forum. Participation lasts approximately 12 weeks from baseline to follow-up.
Actively Recruiting
Researchers are evaluating the safety and tolerability of Efimosfermin Alfa in adults with known or suspected metabolic dysfunction-associated steatohepatitis MASH at fibrosis stages F2 or F3. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how this drug affects participants with this liver condition. Participants will be randomly assigned to one of three groups receiving Efimosfermin Alfa at dose level 1, Efimosfermin Alfa at dose level 2, or a placebo. The treatment is administered as an injection, and the study will track effects and adverse events over 52 weeks. The study includes multiple assessments, including liver fibrosis measurements and blood tests to monitor liver health and other related factors. During the study, participants will undergo regular evaluations including blood tests, imaging scans, and clinical assessments up to Week 52 to monitor safety, liver function, and fibrosis changes. Researchers will measure treatment-emergent adverse events, laboratory abnormalities, and changes in liver fibrosis and fat content using various biomarkers and imaging techniques. This detailed monitoring helps assess the treatments impact and safety profile throughout the study period.
Actively Recruiting
Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.
Actively Recruiting
Researchers are evaluating how well different doses of the medicine BI 3812465 are tolerated in adults with diabetic macular edema that affects the center of the eye. This is the first time BI 3812465 is given to humans. The study includes two parts an initial phase testing low, medium, and high doses sequentially, followed by a phase where more participants receive these doses in a randomized way to assess safety and tolerability. Participants receive BI 3812465 as injections into the back of the eye, with a total of three injections given during the study. In Part 1, a small group receives increasing doses starting from low, and in Part 2, a larger group is randomized to receive one of the three dose levels. The treatment period involves these injections, and dosing only advances if lower doses are tolerated. Participants stay in the study for up to 7 months, attending 19 visits to the study site or, when possible, having visits at their home. During these visits, doctors check the severity of the eye condition and monitor for any health problems related to the medicine. The study measures dose limiting events, ocular adverse events, and other safety outcomes throughout the treatment and follow-up period.
Actively Recruiting
Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.
Actively Recruiting
Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.
Actively Recruiting
Researchers are studying the effects of duvakitug in adults and older teenagers with moderately to severely active Ulcerative Colitis UC, a condition causing inflammation in the colon. This Phase 3 clinical trial is designed to evaluate both the effectiveness and safety of this treatment compared to placebo injections. The study is randomized, double-blind, and takes place at multiple international centers to ensure reliable results. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The trial includes a screening period followed by a 12-week initial treatment phase, with an additional 12-week extended induction period for those who do not respond initially. Participants who do not join the maintenance study will have a 45-day follow-up visit after completing the induction phases. During the study, participants will attend up to 8 visits in the initial treatment phases and up to 15 visits if they continue to the extended induction period. Researchers will assess clinical remission rates, endoscopic improvement, symptom responses, quality of life scores, and safety outcomes such as adverse events and immune responses to the drug. The total study participation may last up to 35 weeks, allowing close monitoring of health and treatment effects throughout.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
1-10 of 14
1